The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients

Most patients with advanced ovarian cancer (OC) relapse and progress despite systemic therapy, pointing to the need for improved and tailored therapy options. Functional precision medicine can help to identify effective therapies for individual patients in a clinically relevant timeframe. Here, we p...

Full description

Saved in:
Bibliographic Details
Published in:NPJ precision oncology 2023-10, Vol.7 (1), p.111-111, Article 111
Main Authors: Åkerlund, Emma, Gudoityte, Greta, Moussaud-Lamodière, Elisabeth, Lind, Olina, Bwanika, Henri Colyn, Lehti, Kaisa, Salehi, Sahar, Carlson, Joseph, Wallin, Emelie, Fernebro, Josefin, Östling, Päivi, Kallioniemi, Olli, Joneborg, Ulrika, Seashore-Ludlow, Brinton
Format: Article
Language:English
Subjects:
631/67/1517/1709
692/4028/67/1517/1709
Cancer Research
Cancer therapies
Drug efficacy
Drug testing
Drugs
Gene Therapy
Gynecology
Human Genetics
Internal Medicine
Kinases
Medicin och hälsovetenskap
Medicine
Medicine & Public Health
Obstetrics
Oncology
Ovarian cancer
Pathology
Patients
Precision medicine
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Most patients with advanced ovarian cancer (OC) relapse and progress despite systemic therapy, pointing to the need for improved and tailored therapy options. Functional precision medicine can help to identify effective therapies for individual patients in a clinically relevant timeframe. Here, we present a scalable functional precision medicine platform: DET3Ct (Drug Efficacy Testing in 3D Cultures), where the response of patient cells to drugs and drug combinations are quantified with live-cell imaging. We demonstrate the delivery of individual drug sensitivity profiles in 20 samples from 16 patients with ovarian cancer in both 2D and 3D culture formats, achieving over 90% success rate in providing results six days after operation. In this cohort all patients received carboplatin. The carboplatin sensitivity scores were significantly different for patients with a progression free interval (PFI) less than or equal to 12 months and those with more than 12 months ( p  
ISSN:2397-768X
2397-768X
DOI:10.1038/s41698-023-00463-z